Search results for "Metastasis"

showing 10 items of 986 documents

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final…

2016

Summary Background FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer. The same study also reported an exploratory analysis of a subgroup of patients with tumours that were wild-type at other RAS genes ( KRAS and NRAS exons 2–4). We report here efficacy results for the FIRE-3 final RAS ( KRAS/NRAS , exons 2–4) wild-type subgroup. Moreover, new metrics of tumour dynamics were explored during a centralised radiological review to investigate how FOLFIRI plus cetuximab conferred overall survival benefit in the absence of differences in investigator-assess…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyBevacizumabColorectal cancerPopulationLeucovorinCetuximabmedicine.disease_cause03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasiseducationResponse Evaluation Criteria in Solid TumorsAgededucation.field_of_studyCetuximabbusiness.industryMiddle Agedmedicine.diseaseIrinotecanBevacizumab030104 developmental biologyGenes rasOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleKRASFluorouracilbusinessColorectal NeoplasmsTomography X-Ray Computedmedicine.drugThe Lancet. Oncology
researchProduct

Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations.

2017

Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineSurgical oncologyCeliac ArteryInternal medicinemedicineHumansYoung adultCystadenocarcinomaSurvival rateLymph nodeAgedRetrospective StudiesOvarian Neoplasmsbusiness.industryLiver NeoplasmsRetrospective cohort studyCytoreduction Surgical ProceduresMiddle Agedmedicine.diseaseovarian cancer hepatoceliac lymph nodes metastasesPrognosisCystadenocarcinoma SerousEndometrial NeoplasmsSurvival Rate030104 developmental biologymedicine.anatomical_structureSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisSurgery; OncologyAdenocarcinomaLymph Node ExcisionSurgeryFemaleLymph NodesbusinessAdenocarcinoma Clear CellFollow-Up StudiesAnnals of surgical oncology
researchProduct

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study.

2017

Abstract Purpose Visceral metastasis of breast cancer (BC) is an alarming development and correlates with poor median overall survival. The purpose of this retrospective study is to examine the risk factors for developing visceral metastasis by considering tumor biology and patient characteristics. Methods Using the BRENDA database, the risk factors such as histological and intrinsic subtypes of BC, age at primary diagnosis, grading, nodal status, tumor size and year of primary diagnosis were examined in univariate and multivariate analysis. Categorical variables were compared by using χ2 tests. Furthermore, multivariate Cox proportional hazards regression models, Kaplan–Meier product-limit…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyMultivariate statisticsMultivariate analysisLung NeoplasmsBreast NeoplasmsKaplan-Meier EstimateLogistic regressionMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerRisk FactorsInternal medicineMedicineHumansGrading (tumors)AgedProportional Hazards ModelsRetrospective StudiesAged 80 and overChi-Square Distributionbusiness.industryCarcinoma Ductal BreastLiver NeoplasmsUnivariateAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyLogistic Models030220 oncology & carcinogenesisMultivariate AnalysisSurgeryFemalebusinessBreast (Edinburgh, Scotland)
researchProduct

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French P…

2016

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Cote d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan–Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8–53.8%] versus 44.5…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsDiseaseKaplan-Meier EstimateMetastasis03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineEpidemiologyInternal MedicinemedicineHumansRegistriesskin and connective tissue diseaseseducationSurvival rateAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisSurgeryFemaleFrancebusinessThe breast journal
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

2021

Purpose: To evaluate immune cell infiltration, the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) expression and their prognostic value in a series of mismatch proficient (pMMR) CRC with matched liver and lung metastases. Methods: Formalin-fixed paraffin-embedded tissue sections stained for CD3, CD8, PD-L1 and PD-1 from 113 primary CRC tumours with 105 liver and 59 lung metastases were analyzed. The amount of CD3 and CD8 positive lymphocytes were combined as immune cell score (ICS). Comparative analyses on immune contexture were performed both between the primary tumour and matched metastases and between the metastatic sites. Results: In liver metastases, immune cell infiltration…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyColorectal cancerCD3CellMetastasis03 medical and health sciences0302 clinical medicineImmune systemPD-L1Internal medicinemedicineLungbiologybusiness.industrymedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbiology.proteinbusinessCD8Cancers
researchProduct

“Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity…

2020

Simple Summary Despite the enormous advance in biomarker discovery, many potential biomarkers of drug activity are unable to satisfy the clinical need due to inadequate sensitivity and specificity. The nucleoside transporter hENT-1 has been studied as a potential biomarker to predict the effect of the widely used anticancer drug gemcitabine in pancreatic cancer. However, several studies showed controversial results regarding the predictive value of hENT-1, prompting new analyses with larger cohorts of patients and standardized methodologies. Improved insights on molecular mechanisms underlying hENT-1 expression and activity should also help in the identification of subsets of patients who a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFOLFIRINOXpancreatic cancerSettore BIO/05 - Zoologiaclinical outcomeDUCTAL ADENOCARCINOMAEquilibrative nucleoside transporter 1lcsh:RC254-282Articlehuman equilibrative nucleoside transporter 103 medical and health sciences0302 clinical medicinePancreatic cancerInternal medicinemedicine1112 Oncology and CarcinogenesisScience & Technologydrug resistanceROLESNucleoside analoguebiology1 HENT1business.industryCombination chemotherapyCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineRegimenLEVELS PREDICT RESPONSE030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSMETASTASISbiology.proteinSURVIVALBiomarker (medicine)ADJUVANT GEMCITABINEbusinessLife Sciences & BiomedicineRESISTANCEmedicine.drug
researchProduct

Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis

2018

Background: Recent studies evaluated the diagnostic accuracy of circulating tumor DNA (ctDNA) analysis in the detection of epidermal growth factor receptor (EGFR) mutations from plasma of NSCLC patients, overall showing a high concordance as compared to standard tissue genotyping. However it is less clear if the location of metastatic site may influence the ability to identify EGFR mutations. Objective: This pooled analysis aims to evaluate the association between the metastatic site location and the sensitivity of ctDNA analysis in detecting EGFR mutations in NSCLC patients. Methods: Data from all published studies, evaluating the sensitivity of plasma-based EGFRmutation testing, stratifi…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsGenotypeSettore MED/06 - Oncologia MedicaConcordanceEGFRintrathoracicReal-Time Polymerase Chain ReactionNSCLCMetastasisCirculating Tumor DNACohort Studies03 medical and health sciencesT790M0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansmetastasisLiquid biopsyNeoplasm MetastasisLung cancerGenotypingextrathoracicEGFR; NSCLC; ctDNA; extrathoracic; intrathoracic; liquid biopsy; metastasisPharmacologyChi-Square Distributionliquid biopsybusiness.industryOdds ratioctDNAmedicine.diseaseConfidence intervalData AccuracyErbB Receptors030104 developmental biologyOncology030220 oncology & carcinogenesisMutationHuman medicinebusiness
researchProduct

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

2021

Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and l…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNeoplasm metastasisAge at diagnosisPrognoseDiagnostic accuracylcsh:RC254-282ArticleMetastasis03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinebrain metastasesOverall survivalBrustkrebsMedicineddc:610HirnmetastaseUnivariate analysisbusiness.industryBrainLuminal aLuminal blcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosis030104 developmental biologyOncology030220 oncology & carcinogenesisBreast; CancerPrognostic groupBreast neoplasmsbusinessDDC 610 / Medicine & healthprognostic scoresCancers
researchProduct

Features associated with melanoma metastasis in Latvia

2020

Cutaneous melanoma (CM) is the most aggressive form of skin cancer, exhibits an increasing incidence worldwide and has a high potential to develop metastasis. The current study aimed to identify a set of parameters that may aid in predicting the probability and timing of the onset of CM metastasis. A retrospective analysis was performed using the archive data of 2,026 patients with CM that were treated at the Riga East University Hospital Latvian Oncology Centre, which is the largest oncological hospital in the country, between 1998 and 2015. A case-control study design was employed, where patients with metastasis (n=278) were used as the cases and patients without metastasis were used as t…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyRate ratiosurvivalMetastasisBreslow Thickness03 medical and health sciences0302 clinical medicinepigmentInternal medicinemelanomamedicinemetastasisbusiness.industryMelanomaCancerArticlesOdds ratiomedicine.diseaseulceration030104 developmental biologyOncology030220 oncology & carcinogenesisCutaneous melanomaprognosisSkin cancerbusinessBreslow thicknessOncology Letters
researchProduct